ClinicalTrials.gg
CompletedNCT06438757Updated Jun 15, 2026

Trial of JYB1904 in Patients With Allergic Asthma

A Phase 2 interventional study of JYB1904 and Omalizumab in Allergic Asthma, sponsored by Jemincare. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Jemincare · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
135th of 182
69 · median 203
Started
2024
with 37 others
Phase 2
39 of 251
19 open now
Registered
163rd of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 135th largest by enrollment of the 182 interventional ones that give a count, is one of 38 that started in 2024, is one of 39 in phase 2, and was the 163rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.

03

Conditions studied

  • Allergic Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide written voluntarily;
  • Aged 18-75 years, weight ≥ 40 kg, male or female;
  • Diagnosed Allergic asthma.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to anti-IgE therapy within 1 year;
  • Allergic to anti-IgE biologics;
  • Current smokers, or quit smoking within 1 year;
  • Combined with other non-allergic diseases that cause IgE elevation;
  • History of , diseases, Immune complex mediated diseases, Hypereosinophilic syndrome;
  • Other conditions unsuitable for the trial judged by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    JYB1904: Dose-1

    Drug: JYB1904

  • Experimental
    JYB1904: Dose-2

    Drug: JYB1904

  • Experimental
    JYB1904: Dose-3

    Drug: JYB1904

  • Active comparator
    Omalizumab

    Drug: Omalizumab

Interventions

  • Participants will receive JYB1904 every 8 weeks for 24 weeks.

  • Participants will receive Omalizumab every 2/4 weeks for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Serum concentrations of JYB1904

    Serum concentrations of JYB1904, assessed by pre-specified methods

    Time frame: Baseline through 337 days post-dose

  2. Serum concentrations of IgE

    Serum concentrations of IgE, assessed by pre-specified methods

    Time frame: Baseline through 337 days post-dose

  3. Adverse Events(AEs)

    Incidence and features of AEs assessed by CTCAE v5.0, and related safety parameters analysis

    Time frame: Baseline through 337 days post-dose

Secondary outcomes

  1. Times of protocol-defined asthma exacerbations during the 24-week treatment period

    Times of protocol-defined asthma exacerbations during the 24-week treatment period

    Time frame: Baseline through 168 days post-dose

  2. Change in spirometry measures of forced expiratory volume in one second (FEV1) in 24 weeks

    forced expiratory volume in one second (FEV1)

    Time frame: Baseline through 24 weeks post-dose

  3. Serum concentrations of anti-drug antibody (ADA)

    Serum ADA assessed by pre-specified methods, and related immunogenic features analysis

    Time frame: Baseline through 337 days post-dose

07

Study locations

1 site
  • Shanghai General Hospital
    Shanghai, Shanghai Municipality 201203, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Nov 2025, 17 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 17 months is close to that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2024
First posted
Jun 3, 2024
StartActual
Jun 19, 2024
Primary completionActual
Nov 20, 2025
CompletionActual
Dec 20, 2025
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06438757
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Jun 3, 2024
Start date
Jun 19, 2024
Primary completion
Nov 20, 2025
Completion
Dec 20, 2025
Last update
Jun 15, 2026

Study contacts

Min Zhang
study chair · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ozureprubart

Start the discussion